HIV-Tat upregulates the expression of senescence biomarkers in CD4+ T-cells., PMID:40342418
HIV-Tat upregulates the expression of senescence biomarkers in CD4+ T-cells., PMID:40342418
Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma., PMID:40317602
Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma., PMID:40317602
Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study., PMID:40275185
Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study., PMID:40275185
Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer., PMID:40154091
Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer., PMID:40154091
Analysis of the Predictive Efficacy of Serum suPAR Combined with APN and IgE Test and the Relationship of Patients with CHF and Cardiac Function., PMID:38581326
Analysis of the Predictive Efficacy of Serum suPAR Combined with APN and IgE Test and the Relationship of Patients with CHF and Cardiac Function., PMID:38581326
Analysis of Circulating Tumor and Cancer Stem Cells Provides New Opportunities in Diagnosis and Treatment of Small Cell Lung Cancer., PMID:36142766
Analysis of Circulating Tumor and Cancer Stem Cells Provides New Opportunities in Diagnosis and Treatment of Small Cell Lung Cancer., PMID:36142766
Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome., PMID:35102231
Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome., PMID:35102231
Mitofusin-2 regulates leukocyte adhesion and β2 integrin activation., PMID:34494308
Mitofusin-2 regulates leukocyte adhesion and β2 integrin activation., PMID:34494308
A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma., PMID:33561783
A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma., PMID:33561783
Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study., PMID:32706905
Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study., PMID:32706905
Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions., PMID:32069085
Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions., PMID:32069085
Soluble Urokinase Receptor and Acute Kidney Injury., PMID:31995687
Soluble Urokinase Receptor and Acute Kidney Injury., PMID:31995687
Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes., PMID:31449183
Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes., PMID:31449183
Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer., PMID:31176112
Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer., PMID:31176112
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins αMβ2 and αVβ3., PMID:29852400
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins αMβ2 and αVβ3., PMID:29852400
Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis., PMID:26622860
Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis., PMID:26622860
Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography., PMID:26504891
Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography., PMID:26504891
Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation., PMID:25659907
Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation., PMID:25659907
Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese., PMID:25500737
Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese., PMID:25500737
Ex vivo paracrine properties of cardiac tissue: Effects of chronic heart failure., PMID:25175803
Ex vivo paracrine properties of cardiac tissue: Effects of chronic heart failure., PMID:25175803
Cadmium induces urokinase-type plasminogen activator receptor expression and the cell invasiveness of human gastric cancer cells via the ERK-1/2, NF-κB, and AP-1 signaling pathways., PMID:25069788
Cadmium induces urokinase-type plasminogen activator receptor expression and the cell invasiveness of human gastric cancer cells via the ERK-1/2, NF-κB, and AP-1 signaling pathways., PMID:25069788
Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM)., PMID:24465541
Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM)., PMID:24465541
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy., PMID:23842190
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy., PMID:23842190
Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2., PMID:23709605
Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2., PMID:23709605
Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells., PMID:22634564
Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells., PMID:22634564
Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration., PMID:22280367
Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration., PMID:22280367
Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor., PMID:22203761
Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor., PMID:22203761
Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation., PMID:21223347
Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation., PMID:21223347
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis., PMID:20967855
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis., PMID:20967855
Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy., PMID:18794071
Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy., PMID:18794071
Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro., PMID:18781095
Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro., PMID:18781095
Urokinase-type plasminogen activator receptor induces conformational changes in the integrin alphaMbeta2 headpiece and reorientation of its transmembrane domains., PMID:18644795
Urokinase-type plasminogen activator receptor induces conformational changes in the integrin alphaMbeta2 headpiece and reorientation of its transmembrane domains., PMID:18644795
PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity., PMID:18387948
PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity., PMID:18387948
Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells., PMID:18247343
Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells., PMID:18247343
Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor., PMID:18245952
Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor., PMID:18245952
Serum markers for prostate cancer: a rational approach to the literature., PMID:18243505
Serum markers for prostate cancer: a rational approach to the literature., PMID:18243505
Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression., PMID:18189329
Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression., PMID:18189329
Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells., PMID:17970088
Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells., PMID:17970088
uPA binding increases UPAR localization to lipid rafts and modifies the receptor microdomain composition., PMID:17963689
uPA binding increases UPAR localization to lipid rafts and modifies the receptor microdomain composition., PMID:17963689
Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice., PMID:17723133
Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice., PMID:17723133
Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer., PMID:17706320
Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer., PMID:17706320
Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors., PMID:17686008
Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors., PMID:17686008
Urokinase receptor variants in tissue and body fluids., PMID:17682340
Urokinase receptor variants in tissue and body fluids., PMID:17682340
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo., PMID:17549305
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo., PMID:17549305
The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis., PMID:17517866
The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis., PMID:17517866
A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines., PMID:17509140
A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines., PMID:17509140
Characterization of the rat urokinase plasminogen activator receptor promoter in PC12 cells., PMID:17455298
Characterization of the rat urokinase plasminogen activator receptor promoter in PC12 cells., PMID:17455298
[Membrane and cytoplasmic expression of urokinase-type plasminogen activator receptor in synovial tissues of rheumatoid arthritis patients]., PMID:17445440
[Membrane and cytoplasmic expression of urokinase-type plasminogen activator receptor in synovial tissues of rheumatoid arthritis patients]., PMID:17445440
The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells., PMID:17344041
The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells., PMID:17344041
Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy., PMID:17330942
Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy., PMID:17330942
For research use only. Not for human or drug use.
